
The article summarizes a clinical trial comparing sublobar resection and lobectomy in patients with small-sized peripheral non-small-cell lung cancer (NSCLC). The trial was conducted between June 2007 and March 2017 and involved 697 patients with T1aN0 stage NSCLC. The primary endpoint of the trial was disease-free survival, with secondary endpoints of overall survival, recurrence, and pulmonary functions. Results showed that sublobar resection was non-inferior to lobectomy for disease-free survival and overall survival. No substantial difference was observed in the incidence of locoregional or distant recurrence between the two groups. The study was funded by the National Cancer Institute and others.
Like
Save
Share